Virginia B. Kraus
Duke University
497 Papers
2.1K Citations
Virginia B. Kraus is an academic researcher from Duke University. The author has contributed to research in topics: Medicine & Osteoarthritis. The author has an hindex of 75, co-authored 452 publications. Previous affiliations of Virginia B. Kraus include Howard Hughes Medical Institute & Research Triangle Park.
Chat about Author
Papers
Genome-wide association meta-analyses to identify common genetic variants associated with hallux valgus in Caucasian and African Americans
Yi-Hsiang Hsu,Youfang Liu,Marian T. Hannan,William Maixner,Shad B. Smith,Luda Diatchenko,Yvonne M. Golightly,Hylton B. Menz,Virginia B. Kraus,Michael Doherty,Anthony G. Wilson,Joanne M. Jordan +11 more
TL;DR: The first genome-wide association study (GWAS) aimed to identify genetic variants associated with HV suggests contribution of biological pathways observed in osteoarthritis as well as new pathways, influencing skeletal development and inflammation.
Imaging Biomarker Validation and Qualification Report: Sixth OARSI Workshop on Imaging in Osteoarthritis combined with Third OA Biomarkers Workshop
David J. Hunter,Felix Eckstein,Virginia B. Kraus,Elena Losina,Elena Losina,Linda J. Sandell,Ali Guermazi,Ali Guermazi +7 more
TL;DR: The OA research communities need to work alongside regulatory agencies across the world, to qualify and validate new chemical and imaging biomarkers for future research and clinical trials.
22
High prevalence of contralateral ankle abnormalities in association with knee osteoarthritis and malalignment
TL;DR: Results are consistent with a probable kinematic association of knee OA pathology and contralateral ankle abnormalities and suggest that interventions targeting mechanical factors may be needed to prevent ankle OA in the setting of knee osteoarthritis.
22
Effect of Aging on Adipose Tissue Inflammation in the Knee Joints of F344BN Rats
TL;DR: Although aging promotes osteoarthritis risk by increasing basal inflammation, the findings also revealed a potentially protective effect of aging by decreasing IL-1β-stimulated leptin production.
21
FDA/Arthritis Foundation osteoarthritis drug development workshop recap: Assessment of long-term benefit.
Jason S. Kim,Silvana Borges,Daniel J. Clauw,Philip G. Conaghan,David T. Felson,Thomas R. Fleming,Rachel Glaser,Elizabeth Hart,Marc C. Hochberg,Yura Kim,Virginia B. Kraus,Larissa Lapteva,Xiaojuan Li,Sharmila Majumdar,Timothy E. McAlindon,Ali Mobasheri,Tuhina Neogi,Frank W. Roemer,Rebecca Rothwell,Robert B Shibuya,Jeffrey Siegel,Lee S. Simon,Kurt P. Spindler,Nikolay P. Nikolov +23 more
TL;DR: The state of the art in the field of OA is discussed in this paper , where the authors discuss the current state of science in the disease of osteoarthritis, identify the knowledge gaps, and examine the developmental and regulatory challenges in bringing these products to market.
20